Efficacy and safety of tocilizumab in treatment of Takayasu arteritis: A systematic review of randomized controlled trials

Takayasu arteritis (TAK) is a chronic immune vasculitis in which Interleukin-6 (IL-6) receptors play a key role in pathogenesis. Tocilizumab (TCZ), an IL-6 receptor antagonist with a favorable safety and efficacy profile, has been tried as an option for patients with TAK. This systematic review analyzed the evidence from randomized control trials (RCT) assessing the safety and efficacy of TCZ in patients with TAK.

高安动脉炎（Takayasu arteritis, TAK）是一种慢性免疫性血管炎，其中白细胞介素-6（Interleukin-6, IL-6）受体在其发病机制中发挥关键作用。托珠单抗（Tocilizumab, TCZ）作为一款安全性与有效性表现良好的IL-6受体拮抗剂，已被尝试作为TAK患者的治疗选择。本系统综述分析了评估托珠单抗用于TAK患者的安全性与有效性的随机对照试验（Randomized Control Trial, RCT）证据。